Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2012-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous
(SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).